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Abstract 
 The aim of this study was to explore the anti-inflammatory properties of 
phosphodiesterases-4 (PDE4) inhibitors in vivo and their potential ability to prevent 
inflammation-induced preterm delivery. Indeed, intrauterine inflammation is the major etiology 
of very preterm delivery, the leading cause of neonatal mortality and morbidity. Intrauterine 
injection of Escherichia Coli LPS in 15 day pregnant mice induced an increase of PDE4 activity 
and PDE4B expression at the materno-fetal interface, a rise of amniotic fluid levels of TNFα, 
IL1β, IL6 and IL10,  and provoked massive preterm delivery and fetal demise. Selective PDE4 
inhibition by rolipram prevented the rise in the proinflammatory cytokines. Following the nuclear 
translocation of the transcription factor NFκB, as a marker of cellular activation after the 
inflammatory challenge, showed a time dependent sequential activation of the gestational tissues, 
from the uterine mesometrial to the fetal compartment, particularly in the glycogen trophoblastic 
cells of the placenta. This activation was disrupted by PDE4 inhibition, and inflammation-
induced preterm delivery and fetal demise were prevented. PDE4 selective inhibitors may thus 
represent a novel effective treatment to delay inflammation-induced preterm delivery and to 
prevent adverse outcomes in infants. 
 2
H
al author m
anuscript    inserm
-00112464, version 1
 Introduction 
 In industrialized countries, 5-11% of infants are born preterm, before 37 weeks of 
postmenstrual age (PMA). Very preterm delivery (before 32 weeks PMA) accounts for 70% of 
neonatal deaths and up to 75% of neonatal morbidity and contributes to long-term neurocognitive 
deficits and pulmonary dysfunction. Intrauterine infection has been recognized as the primary cause 
of very preterm delivery and favors development of periventricular leukomalacia and 
bronchopulmonary dysplasia (1-3). Often clinically silent, intrauterine infection triggers at the 
materno-fetal interface a feedforward inflammatory mechanism involving the production of 
cytokines, potent uterotonics and metalloproteases, which results in preterm cervical ripening, uterine 
contraction, and rupture of the membranes and ultimately ends by preterm delivery. Studies in 
Humans demonstrated higher amniotic fluid concentrations of IL-6, TNFα, and many other cytokines 
and chemokines in patients who subsequently delivered preterm than in patients who delivered at 
term (4).  Systemic or intrauterine injection of IL-1β, TNFα, killed bacteria, or bacterial products 
induces preterm delivery in pregnant mice, rabbits, sheeps, or monkeys (5). 
 The cyclic nucleotides phosphodiesterases (PDE) are the enzymes that hydrolyze the 
ubiquitous second messengers, cAMP and cGMP, involved in the regulation of a wide variety of 
physiological processes including smooth muscle contractility, inflammation, and neuronal 
development. Eleven families of PDE are described to date with different affinities for cyclic 
nucleotides, specific modulators, and different patterns of expression (6). Their expression and 
regulation define the duration and the intensity of the signal generated by the cyclic nucleotides, 
building thus the specificity of the biological response.   
 Selective inhibitors of some PDE families are currently used in clinical practice for the 
 3
H
al author m
anuscript    inserm
-00112464, version 1
treatment of cardiovascular disorders and erectile dysfunction and other PDE inhibitors are under 
development for the treatment of central nervous system and inflammatory disorders. The PDE4 
family is one of the major PDE family controlling inflammation. PDE4 represents the major 
cAMP hydrolyzing enzyme family in all immunocompetent cells. Human monocytes and 
neutrophils present a predominant PDE4 activity (7) and PDE4 inhibitors suppress monocytes 
and macrophages production of TNFα, adhesion and chemotaxis of neutrophils, as well as 
superoxide production and degranulation (8). The mammalian PDE4 family is encoded by four 
genes A, B, C, and D, composed of multiple transcriptional units and multiple promoters, which 
generate at least 20 different PDE4s (9). PDE4B products are thought to be specifically involved 
in inflammation (7, 10-12).  
Herein, we investigate the ability of a PDE4 selective inhibitor, rolipram, to prevent in 
vivo preterm delivery and fetal demise in a murine model of intrauterine inflammation. 
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Materials and Methods 
Animals 
 Procedures that involved mice were approved by our Institutional Committee on Animal 
Use and Care and were conducted in strict accordance with guidelines for the use and care of 
laboratory research animals promulgated by the NIH. CD-1 timed-pregnant mice were purchased 
from Charles River Laboratories (L’Arbresle, France). Animals were shipped on day 12 after 
mating and were acclimated in our facility for 3 days before use.  
 
Mouse model of inflammation-induced preterm delivery 
 On day 15 of gestation (75% CD-1 gestation), a mini-laparotomy was performed under 
general anesthesia in the lower abdomen. Ten μg of LPS of Escherichia coli (O127:B8, Sigma, St 
Louis, MO) were injected in 100 μl PBS between the first two gestational sacs of the left uterine 
horn according to the technique of Elovitz et al. (13). Control animals received 100 μl of sterile 
PBS. Animals recovered in individual cages and were observed closely for any sign of morbidity 
(piloerection, decreased movements, vaginal bleeding). Two hours after surgery, mice received 
an intraperitoneal injection of 100 μl PBS containing either rolipram (3 mg/kg) or vehicle (5% 
DMSO). Preterm delivery was defined by delivery of at least one pup within the 48 hours 
following surgery. Forty-eight hours after surgery, undelivered mice were placed under general 
anesthesia and the number of live and dead pups in each horn was recorded. Intrauterine fetal 
deaths were identified by white discoloration of the pup and placenta and lack of blood flow in 
the umbilical cord. 
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Histochemistry and Immunohistochemistry 
 For tissue collections, mice were killed two, four or six hours after surgery. Cervical 
tissue and intact utero-placental units were harvested and either fixed in 10% formalin and 
embedded in paraffin, or snap frozen. Cervix structures were identified on 5 μm paraffin by 
Masson’s Trichrome stain. For uterine and placenta histology and immunohistochemistry, direct 
adjacent sections were processed either for periodic acid-Schiff reaction (PAS), for NFκB or 
uterine NK (uNK) cells detection. Briefly, slides were deparaffinized through two rinses in 
xylene (Prolabo, Paris, France) and rehydrated through graded ethanol to phosphate-buffered 
saline (PBS pH 7.4) or to deionized water. To detect NFκB expression, we used the polyclonal 
antibody directed against the p65 form of the protein (Biosciences, Montrouge, France) diluted to 
1:1,000 in PBS-BSA 1%-Triton 0.05%.  To detect uNK cells, we used HRP-Dolichos biflorus 
(DBA) lectin (Sigma) diluted to 200 μg/ml in PBS-BSA 1% (14). Incubation was processed for 
24h at 4oC and after successives rinses, endogenous peroxidase activity was blocked with 3% 
hydrogen peroxide. In final, immunoreactivity was detected using the avidin-biotin Vectastain 
ABC Elite kit (Vector laboratories, Burlingame, CA). Color development was performed using 
Sigma Fast diaminobenzidine and tissue section were counterstained with Mayer’s haematoxylin 
solution (Merck, Darmstadt, Germany). Non specific labeling by NFκB antibody was assessed on 
direct adjacent sections by incubation with normal rabbit serum instead of the primary antibody 
or by omitting the primary antibody. In both cases, immunostaining was abolished. NFκB 
expression and uNK cell number were analyzed by two investigators under microscope equipped 
with a DC 300 F camera (DMR, IM 1000) (Leica, Nussloch, Germany) using different 
magnifications.  
 
Quantification of immunohistochemistry 
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Positively stained nuclei were counted at x200 magnification. Nuclei were counted in five 
distinct random fields per section, limited to the placental junctional zone and the adherent 
decidua basalis. The average number of positive nuclei per 1 mm2 for each tissue sample was 
used for statistical analysis. All sections were counted by a single blinded investigator for internal 
consistency. Random sections were counted by a blinded independent investigator for external 
verification of the results.  
 
Cytokines measurement in amniotic fluid 
 The amniotic fluids from the two gestational sacs adjacent to the site of injection were 
collected and snap frozen. Measurements of IL-1β, IL-6, TNFα, and IL-10 concentrations were 
performed using the SearchlightTM multiplex sample testing by Endogen, PerbioScience 
(Brebieres, France).  
 
Progesterone measurement in dam plasma 
 Blood was collected by sinus orbital puncture under anesthesia, 6h after LPS instillation. 
Plasma samples were analyzed for progesterone concentration in duplicate by direct RIA, as 
previously described by Schanbacher (15) with some modifications. Charcoal-dextran solution 
was used instead of polyethylene glycol for the separation of bound and free radioactivity. 
Tritiated progesterone (1,2,6,7-3H-progesterone, sp act 88 Ci/mmol) was obtained from 
Amersham, and a specific antiprogesterone antibody was obtained from the Pasteur Institute 
(Paris, France). To minimize assay variability, all plasma samples were analyzed in a single RIA. 
The limit of assay sensitivity was 0.1 ng/ml, and the intra-assay coefficient of variation was less 
than 10%.  
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cAMP-phosphodiesterase assay 
 Uterine and decidual-placental units were homogenized in ice-cold hypotonic buffer (Tris-
HCl 20 mM pH 8.0, NaF 50 mM, EDTA 1 mM, EGTA 0.2 mM, Na2PO4 10 mM, ß-
mercaptoethanol 5 mM, and a protease inhibitor cocktail: leupeptin 0.5 µg/ml, aprotinin 4 µg/ml, 
benzamidine 50 mM, pepstatin 0.7 µg/ml, soybean trypsin inhibitor 10 µg/ml, and PMSF 10 
µg/ml added freshly before use) using an all-glass homogenizer. Aliquots of the homogenates 
were assayed for cAMP PDE activity according to the method of Thompson and Appleman (16). 
PDE activities were measured with 1 µM [3H]-cAMP as a substrate. PDE4 activity was defined 
as the fraction of cAMP PDE activity inhibited by 10 µM rolipram. Protein concentrations were 
determined using the Bio-Rad protein assay (Bio-Rad Laboratories, Inc., Hercules, CA) with 
BSA as a standard. 
 
Western blot analysis  
 Samples (30 µg protein/lane) were boiled in Laemmli buffer, subjected to electrophoresis 
on a 10% SDS-PAGE, and blotted onto Hybond-P transfer membrane (Amersham Pharmacia 
Biotech, Inc., Piscataway, NJ). Membranes were blocked in TBS-Tween 20 0.1% containing 5% 
nonfat milk. Polyclonal anti-PDE4B, (K118, 1:1,000, gift of M. Conti, Stanford University) were 
used (17). Second-step horseradish peroxidase-conjugated anti-rabbit antibodies (1:5,000) were 
purchased from Amersham (Amersham Pharmacia) and visualized by use of the ECL detection 
reagents (Amersham Pharmacia Biotech, Inc.). 
 
Data analysis  
 Unless otherwise stated, significance of the difference was assessed by two-way ANOVA 
followed by Student's t test, two tailed for unpaired samples using the Prism-Graph Pad software 
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(GraphPad Software, San Diego, CA, USA). The difference was considered significant when P < 
0.05. 
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Results 
Blockade of inflammation-induced preterm delivery and reduction of fetal demise by rolipram. 
 Intrauterine injection of LPS provoked preterm delivery in 11 of 13 treated animals with 
full emptiness of the two uterine horns at 48h post-surgery. Despite maintaining pregnancies, the 
two remaining LPS-treated dams experienced massive in utero fetal deaths (75%) (Table I). 
However no maternal mortality or morbidity was observed. Uterine infusion of saline solution or 
rolipram alone resulted in minimal preterm delivery and in minimal fetal demise, only observed 
at the insert of the intrauterine injection. Treatment with rolipram 2h after the LPS injection 
blocked preterm delivery and significantly reduced fetal demise (22%). 
  
Inhibition of inflammation-induced cervical ripening by rolipram. 
 Cervical ripening is characterized by a dispersion of collagen fibers of the stroma and by 
increase in the mucin secretion (18). To document the onset of preterm labor induced by LPS and 
its prevention by rolipram, sections of cervical tissue from the four groups of animals, saline- or 
LPS-injected with or without rolipram, were mounted and assessed for histological aspect and 
collagen organization with a Masson’s Trichrome stain. In the LPS-injected group, 6h post-
surgery, the glandular epithelium showed increased volume of the epithelial glands containing 
secretory vacuoles. Trichrome staining revealed loose array of disordered collagen fibers, which 
are histological features of compliant tissue (Figure 1B). In contrast, LPS-injected animals with 
rolipram exhibited characteristic of noncompliant tissue, denser, compact, heavily stain of the 
matrix of collagen fibers associated with undeveloped glands and absence of secretory vacuoles 
in the glandular epithelium as observed in the sham-operated control groups (Figure 1A, 1C, and 
1D).  
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Decrease of inflammation-induced cytokines level rises in amniotic fluid by rolipram. 
 To assess that the onset of preterm labor in LPS-injected dams was concomitant to an 
intrauterine inflammation and that this phenomenon was prevented in the presence of rolipram, 
we measured the concentration of cytokines in amniotic fluids, namely TNFα, IL-1β, IL-6, and 
IL10, which have been reported to be involved in inflammation-induced preterm delivery (19, 
20). As depicted in Figure 2, intrauterine injection of LPS induced a significant increase in the 
concentrations of these cytokines in the amniotic fluid, 6h post-surgery, as compared to the 
saline-vehicle animals, demonstrating that an intrauterine inflammation has been mounted against 
LPS in these animals. The injection of rolipram alone did not significantly affect the 
concentrations of these factors; but it significantly diminished the increase of TNFα, IL-1β, and 
IL-6 concentration in the amniotic fluids of LPS-injected animals while not significantly 
affecting IL-10 concentration. 
 
No change in progesterone plasma levels during intrauterine inflammation. 
 In the same mice, the concentration of circulating progesterone was evaluated 6h post-
surgery. Mice of each group demonstrated high plasma progesterone levels without significant 
difference between the four groups (Figure 3). 
 
Expression of PDE4B2 in decidual and placental units 
 To investigate the level of PDE4 activity in mouse gestational tissues at the time of the 
injection of rolipram, we measured PDE activity in whole homogenates of uterine tissues 
(myometrium and endometrium) or placental units, with the decidual cap still attached, collected 
2h after surgery. As reported in Figure 4, PDE4 activity, gauged as rolipram-sensitive activity, 
represented almost half of total cAMP-PDE activity in both tissues. Uterine tissues contained 10-
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times more cAMP-PDE and PDE4 activities than decidual-placental units, however no change 
was observed upon stimulation by LPS. Meanwhile, PDE4 activity increased significantly in the 
decidua-placental unit. Western blot analysis of PDE4B expression in the decidua-placental unit 
showed an increase in the signal of a short product of PDE4B gene at 72 kDa, corresponding to 
the PDE4B2 form. PDE4B2 was also expressed in uterine tissues, but no change upon LPS 
challenge was observed (Figure 4).  
 
Inhibition of LPS-induced NFκB nuclear translocation in the gestational tissues by rolipram 
 LPS promotes nuclear translocation and activation of the transcriptional factor, NFκB, 
most often found as a p50-p65 dimer unit. The p65 subunit is mainly responsible of the nuclear 
translocation of this complex, a nuclear localization signal being coded within its protein 
sequence (21). Thus, we looked for the cellular localization of p65-NFκB subunit in gestational 
tissues using immunohistochemistry 2, 4, and 6h after surgery (Figure 5). In uterine tissues, p65-
NFκB was readily in the nucleus of endometrial cells in sham-operated animals at H0 and 
remained in the nucleus at 2, 4, and 6h, while rare cytoplasmic signals were detected in the 
myometrium and were not affected by LPS treatment (data not shown).  p65-NFκB was found 
rarely within the nucleus of cells of the decidua-placental units in sham-operated animals at 2 
(Figure 5B), 4, and 6h.  Markedly, a significantly high number of stained nuclei was observed at 
2h in the maternal cells in the decidual cap of LPS-treated animals (Figure 5C). This number of 
stained nuclei remained high at 4h in the maternal compartment and was then also observed in 
the fetal cells of the placenta. At 6h, only glycogen trophoblasts, recognized by their 
characteristic histological aspect and their staining with PAS (22) (Figure 5A), depicted a nuclear 
signal in LPS-treated animals (Figure 5D). Treatment with rolipram abolished the nuclear signals 
in both maternal and fetal compartments (Figure 5E). Quantitative analysis of nuclear NFκB 
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staining demonstrated significant inhibition of nuclear NFκB translocation by rolipram 4 and 6h 
after surgery (Figure 6). 
 
Inhibition of inflammation-induced mesometrial uNK recruitment by rolipram 
 Because uNK cells are the main inflammatory cells within gestational tissues, we checked 
their presence in the decidual cap upon treatment using the highly selective DBA lectin. An 
increase in the number of uNK cells in the mesometrial compartment (Figure 7) 4 hours after 
LPS treatment was observed. This increase was completely prevented in the presence of rolipram. 
However the NFκB nuclear signal and uNK cells were not superposed. 
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Discussion 
 In the present study, we report for the first time that PDE4 inhibition blocks intrauterine 
inflammation in vivo and prevents preterm delivery and fetal demise in a mouse model. We 
provide evidence that intrauterine inflammation evolves from the maternal to the fetal 
compartment. Moreover, our data point out an unrecognized role for the glycogen trophoblasts in 
these processes. 
 Murine models of preterm delivery have been developed these last decades, based on 
systemic or local injection of heated-dead bacteria or bacterial products, including LPS at doses 
ranging from 10 μg to 250 μg, to provide new insights into the molecular events underlying 
causes of preterm labor (reviewed in (5, 21)). Indeed, in Humans, the ethical status of the fetus 
and large discrepancies in clinical variables among patients at the time of asserted preterm labor 
prohibit any possibility to conduct experimentally controlled basic research. The murine preterm 
labor model provides a powerful mean for maintaining tight experimental controls in an in vivo 
context. Using such model we showed that an injection of a low dose of LPS in the uterus 
between two gestational sacs caused 85% of preterm delivery with full emptiness of the uterus 
and 75% of fetal demise in the undelivered dams within 48h. PDE4 inhibition two hours after the 
intrauterine inflammatory challenge blocks preterm labor as documented by the absence of 
morphologic changes in the cervix and subsequent preterm delivery. Furthermore PDE4 
inhibition diminished to more than the third the rate of fetal demise in undelivered dams (22% vs. 
75%), though this figure underestimates the rate of intrauterine death before expulsion in the 
LPS-injected group.  
 We also showed increase in the amniotic fluid concentration of key cytokines 6h after the 
inflammatory challenge, namely, TNFα, IL-1β, IL-6, and IL-10. Elevated levels of TNFα, IL-1β, 
and IL-6 are found in amniotic fluid during pregnancies complicated by infection and preterm 
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delivery in Humans (24). IL-6 level has been proposed as a marker for the prediction of preterm 
delivery (25). TNFα, IL-1β and IL-6 can induce the production of both prostaglandins and 
metalloproteases leading to preterm delivery (19, 20). Double knock-outs for TNFα and IL-1β 
receptors are refractory to bacterially induced preterm labor (22). Conversely, the anti-
inflammatory cytokine IL-10 has been shown to prolong gestation and to diminish fetal demise in 
bacterially treated dams when administrated alone or in combination with antibiotics (23). In our 
model, PDE4 inhibition blocked rise in TNFα, IL-1β, and IL-6, while had no significant effect on 
IL-10 level. Manipulation of these cytokines by PDE4 inhibition may provide a mechanism by 
which rolipram prevents both inflammation-induced delivery and fetal demise.   
 Several compounds have been shown to delay inflammation-induced preterm delivery, 
lactoferrin, betamethasone, pharmacologic doses of progesterone, or a progestin derivative, 
medroxyprogesterone acetate, antioxidant N-acetylcysteine, platelet-activating factor antagonist, 
metalloprotease inhibitor phosphoramidon, PGHS inhibitors such as indomethacin, PGHS-1 and 
PGHS-2 inhibitors, PGF2α receptor antagonist (13, 24-30). Each of these compounds interacts 
with one or more of the factors believed to have a role in the inflammatory cascade leading to 
preterm birth.  However, in all these studies, most of the undelivered fetus died in utero, the rate 
of fetal demises ranging to 60-100%, although the drugs were given before the inflammatory 
challenge, in the contrary to the present study where PDE4 inhibition starts 2h after LPS 
challenge.  
 One major discrepancy between humans and mice gestation consists on the fact that 
maintenance of gestation in mice depends on the production of progesterone by the corpus 
luteum all along the gestation (31). However, despite the fact that physiological progesterone 
supplementation prolongs the interval to delivery in ovariectomized animals, it has no effect in 
bacterially exposed animals, implying that progesterone withdrawal is not the priming event of 
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inflammation-induced preterm delivery . Consistent with others studies, we documented no 
significant decrease in plasmatic progesterone concentration following intrauterine inflammatory 
challenge at a time when labor has started with cervical modification (13, 32). 
 PDE4 inhibition impacts both uterine and decidua-placental tissues, insofar as we 
detected PDE4 activity in these tissues. We documented that PDE4B2, a PDE4 isoform involved 
in inflammation, is induced in the decidual-placental unit by LPS, concomitantly to a significant 
increase in PDE4 activity. These data suggest a role for PDE4B2 in this compartment upon LPS 
inflammatory cascade, while no change of PDE4 activity or PDE4B2 expression was observed in 
the uterine tissues.  
 To identify, within the materno-fetal interface, the cells involved in the LPS inflammatory 
cascade, we searched by immunohistochemistry the localization of NFκB. In our model, we 
observed a sequential nuclear translocation of NFκB from the maternal to the fetal compartment. 
We evidenced nuclear localization of NFκB 2h after the inflammatory challenge in the uterine 
mesometrial compartment (33).We also confirmed an increase of the number of uNK cells after 
the LPS challenge, consistent with earlier report (34). As PDE4B2 expression is reported high in 
immunocompetent cells (35), increase of the number of uNK cells may then account for the 
increased presence of PDE4B2 within the decidual-placental unit. The presence of active uNK 
cells has been shown to be controlled by IL-10 (34). The IL-10 knock-out strain displays high 
uNK cell number in the uterine mesometrial compartment. Moreover this KO strain is highly 
sensitive to very low doses of LPS, which induce massive fetal demise, not seen in the wild-type 
littermates. It has been speculates that uNK cells may serve as a fail-safe mechanism to terminate 
pregnancy, when excessive inflammatory or other insults are experienced (34).  
 Four hours after the LPS insult, NFκ B was also localized in the nucleus of a specific 
trophoblast in the fetal compartment, the glycogen trophoblast. In mice, glycogen trophoblasts 
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appear in the junctional zone of the placenta at 12d and invade the uterine mesometrial 
compartment until term (36, 37). Their functions remain largely unknown; however absence of 
differentiation of these cells in IGF-2 KO strain delays the onset of term labor (38).  Further 
studies on these specialized cells are required to decipher their role in nourishing the feedforward 
mechanisms of intrauterine inflammation to preterm delivery. 
 Interestingly, we showed that the nuclear translocation of NFκB is prevented by PDE4 
inhibition in the cells of the materno-fetal interface, with no more nuclear signal six hours after 
LPS challenge. In a LPS-induced uveitis model in rat, p65-NFκB was also excluded of the 
nucleus of iris-ciliary body of LPS-treated animals by rolipram (39). Therefore, prevention of 
nuclear NFκB translocation may represent a hitherto unnoticed molecular mechanism by which 
rolipram or PDE4 inhibition exerts its antiinflammatory effect.  
 The therapeutic strategy in case of preterm labor, namely tocolysis, is aimed to delay birth 
by inhibiting uterine contractions (40). However, conventional methods of tocolysis are 
ineffective on the inflammation component of preterm labor and expose longer the fetus to 
stimuli noxious for the immature brain. Novel tocolytic agents that down-regulate intrauterine 
inflammation may then offer a solution for the prolongation of pregnancy, safe for the fetus. We 
showed previously in Humans that PDE4 inhibition blocks spontaneous contractions of 
myometrial strips.  It also abolished the activation in fetal membranes of metalloproteases and 
prostaglandin syntheses that may lead to preterm premature rupture of the membranes (41-43). 
Here, we report that PDE4 inhibition blocks intrauterine inflammation, which may injure the 
fetus if uncontrolled. PDE4 inhibitors may thus represent a novel class of tocolytic, also able to 
control inflammation and its consequences for the infant. 
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Figure Legends 
Figure 1-Inhibition of inflammation-induced cervical ripening by rolipram. Cervical sections 
were assessed, 6h after the inflammatory challenge, for histological aspect and collagen content 
(blue-green coloration) using Masson’s trichrome stain. (A) saline-vehicle, (B) LPS-vehicle, (C) 
saline-rolipram, and (D) LPS-rolipram treated animals. Representative sections of the tissues 
obtained from five animals per group are shown. Scale bar = 400 µm
 
Figure 2-Inhibition of inflammation-induced cytokines synthesis in amniotic fluid by rolipram. 
Concentrations of TNFα, Il-1β, Il-6, and IL-10 were measured by multiplex ELISA in amniotic 
fluid of saline-vehicle, saline-rolipram, LPS-vehicle, and LPS-rolipram dams, 6h after LPS 
challenge. Box-and-whisker representations indicate the median and the overall range of 
distribution of the measurements, the bars indicating the smallest and greatest values, obtained 
from 12 different animals. Significant difference from saline-vehicle group: *, P<0.05; **, 
P<0.01. 
 
Figure 3-Progesterone plasma level during intrauterine inflammation. Concentration of 
progesterone was measured by RIA in plasma of saline-vehicle, saline-rolipram, LPS-vehicle, 
and LPS-rolipram dams, 6h after LPS challenge. Box-and-whisker representations indicate the 
median and the overall range of distribution of the measurements, the bars indicating the smallest 
and greatest values, obtained from 12 different animals. 
 
Figure 4-Expression of PDE4B2 in decidual and placental units. (A) Uterine tissues and decidual-
placental unit from saline-vehicle, LPS-vehicle dams, 2h after LPS challenge, were homogenized 
and cAMP PDE activity was measured in the absence or the presence of 10 μM rolipram. Data 
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are expressed as the mean ± SEM for three different experiments using a total of five animals per 
group. *, P<0.05: significantly different from saline-vehicle group. (B) Decidual-placental units 
from saline-vehicle or LPS-vehicle dams for the indicated time were homogenized. Thirty 
micrograms of the protein extracts were subjected to 8% SDS-PAGE and electroblotted. PDE4B 
protein was detected by incubation with the polyclonal antibodies K118 and a peroxydase-
conjugated secondary antibody. Representative blots of three different experiments performed 
with tissues from three different animals are shown.
 
Figure 5-Nuclear localization of NFκB in decidual and placental units during intrauterine 
inflammation. Diagram representing decidual-placental units on 15th gestational days. The square 
represents the regions photographied in the mesometrial side (M), Junctional zone (JZ) and 
Labyrinthe (L). (A) PAS staining of a saline-vehicle dam. (B) and (C) NFkB immunostaining in 
saline-vehicle and LPS-vehicle dams, respectively, 2h after the surgery. (D) and (E) NFkB 
immunostaining in LPS-vehicle and LPS-rolipram dams, respectively, 6h after the surgery. 
Arrowheads indicate glycogen trophoblasts in the junctional zone. Representative sections 
obtained from six different animals per group are shown. Scale bar = 100 µm. 
 
Figure 6-Prevention of sustained NFκB nuclear location by rolipram. Positively NFκB nuclei 
were counted in the decidual-placental unit sections obtained from saline-vehicle, LPS-vehicle, 
saline-rolipram, and LPS-rolipram dams, for the indicated time after LPS challenge. Data are 
expressed as the mean ± SEM obtained from six animals per group. **, P<0.01: significantly 
different from saline-vehicle group. 
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Figure 7-Prevention of uNK cell number increase in gestational tissues by rolipram. Decidual-
placental units were assessed, 4h after the inflammatory challenge, for uNKcells presence using 
the DBA lectin (A) saline-vehicle, (B) LPS-vehicle, (C) saline-rolipram, and (D) LPS-rolipram 
treated animals. Representative sections of the tissues obtained from five animals per group are 
shown. Scale bar = 100 µm. 
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Table I: Prevention of LPS-preterm delivery and fetal demise by rolipram 
 
Treatment group n Preterm delivery
Live pups/ 
undelivered dam (n)
Dead pups/ 
undelivered dam (n)
saline / vehicle 12 1  8.7 ± 1.1 (11) 0.7 ± 0.3 (11) 
LPS / vehicle 13   11*** 2.5 ± 2.5 (2) 7.5 ± 1.5 ( 2) 
saline / rolipram 11 1  10.2 ± 1.5 (10) 0.9 ± 0.5 (10) 
LPS / rolipram 13 2  7.4 ± 1.2 (11)   2.1 ± 0.6* (11) 
 
The Fisher exact test was applied for comparison of preterm delivery rate in each group. *** 
P<0.001 versus saline- vehicle group. For comparison of the number of live and dead pups per 
undelivered dam, expressed as mean ± SEM, statistical difference between groups was assessed 
by two-way ANOVA, followed by Student's t test, two tailed for unpaired samples. * P<0.05, 
versus the saline-vehicle group. 
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Schmitz et al. Figure 4
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